Edwards Lifesciences Corporation $EW Shares Acquired by Trifecta Capital Advisors LLC

Trifecta Capital Advisors LLC lifted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 25,588.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,367 shares of the medical research company’s stock after purchasing an additional 4,350 shares during the period. Trifecta Capital Advisors LLC’s holdings in Edwards Lifesciences were worth $342,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nuveen LLC purchased a new stake in shares of Edwards Lifesciences during the 1st quarter valued at approximately $330,881,000. Jennison Associates LLC raised its position in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after buying an additional 2,576,383 shares during the period. Mirova US LLC raised its position in shares of Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after buying an additional 1,054,301 shares during the period. Woodline Partners LP raised its position in shares of Edwards Lifesciences by 7,805.0% during the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock valued at $59,822,000 after buying an additional 814,917 shares during the period. Finally, AQR Capital Management LLC raised its position in shares of Edwards Lifesciences by 339.7% during the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock valued at $65,381,000 after buying an additional 709,648 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 1.3%

Edwards Lifesciences stock opened at $75.75 on Thursday. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The stock’s fifty day simple moving average is $78.28 and its 200-day simple moving average is $76.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $44.47 billion, a P/E ratio of 10.90, a P/E/G ratio of 3.69 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the company earned $0.70 earnings per share. The company’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on EW shares. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research report on Friday, July 25th. Truist Financial lifted their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research report on Friday, July 25th. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Finally, Stifel Nicolaus set a $85.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a report on Monday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $87.06.

Insiders Place Their Bets

In other news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.